BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/4/2018 12:36:47 PM | Browse: 1097 | Download: 1127
 |
Received |
|
2017-11-28 02:40 |
|
Peer-Review Started |
|
2017-11-28 07:57 |
|
To Make the First Decision |
|
2017-12-11 08:18 |
|
Return for Revision |
|
2017-12-13 09:08 |
|
Revised |
|
2017-12-18 21:40 |
|
Second Decision |
|
2018-01-16 06:39 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2018-01-24 05:10 |
|
Articles in Press |
|
2018-01-24 05:10 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-02-24 03:09 |
|
Publish the Manuscript Online |
|
2018-03-04 12:36 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Giovanni Damiani, Chiara Franchi, Paolo Pigatto, Andrea Altomare, Alessia Pacifico, Stephen Petrou, Sebastiano Leone, Maria Caterina Pace and Marco Fiore |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Marco Fiore, MD, Doctor, Department of Anesthesiological, Surgical and Emergency Sciences, University of Campania “Luigi Vanvitelli”, Piazza Miraglia 2, Naples 80138, Italy. marco.fiore@hotmail.it |
| Key Words |
Hepatitis C virus; New Direct-Acting Antiviral agents; Psoriasis; Biological disease modifying drugs |
| Core Tip |
Psoriasis is a chronic inflammatory disease affecting approximately the 2% of population in Europe and North America. The hepatitis C virus (HCV) infection affects approximately the 3% of the world population with an estimated prevalence of 5 million people in the United States. Up to 0.06% of people in the United States suffer from both psoriasis and HCV. Psoriatic patients with HCV are excluded by randomized controlled clinical trials. Therefore, no data is currently available concerning the concomitant administration of biological disease modifying drugs and the new Direct-Acting Antiviral agents (DAAs) medications approved for the treatment of HCV infection. The aim of this study is to evaluate the outcomes in biological treatment and quality of life of psoriatic patients with HCV infection treated with DAAs compared to the previous standard therapy of Pegylated Interferon plus Ribavirin. |
| Publish Date |
2018-03-04 12:36 |
| Citation |
Damiani G, Franchi C, Pigatto P, Altomare A, Pacifico A, Petrou S, Leone S, Pace MC, Fiore M. Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents. World J Hepatol 2018; 10(2): 329-336 |
| URL |
http://www.wjgnet.com/1948-5182/full/v10/i2/329.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v10.i2.329 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
